CHCWM – Cancer & Hematology Centers of West Michigan

M21-404 (Abbvie)

Description:  Advanced Solid Tumors:   ABBV-400 as Monotherapy-A Global First-in-Human Study

 

Mechanism of Action: Antibody drug conjugate targeting c-MET with a topoisomerase inhibitor payload

 

Target Patient Population: All solid tumors

 

Study Design: Study drug is administered IV every 3 weeks

 

For more information on this trial, read its profile on clinicaltrials.gov here.